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ABSTRACT
Introduction: Transgenic malaria parasites expressing foreign genes, for example fluorescent and
luminescent proteins, are used extensively to interrogate parasite biology and host-parasite interactions
associated with malaria pathology. Increasingly transgenic parasites are also exploited to advance
malaria vaccine development.
Areas covered: We review how transgenic malaria parasites are used, in vitro and in vivo, to determine
protective efficacy of different antigens and vaccination strategies and to determine immunological
correlates of protection. We describe how chimeric rodent parasites expressing P. falciparum or P. vivax
antigens are being used to directly evaluate and rank order human malaria vaccines before their
advancement to clinical testing. In addition, we describe how transgenic human and rodent parasites
are used to develop and evaluate live (genetically) attenuated vaccines.
Expert commentary: Transgenic rodent and human malaria parasites are being used to both identify
vaccine candidate antigens and to evaluate both sub-unit and whole organism vaccines before they are
advanced into clinical testing. Transgenic parasites combined with in vivo pre-clinical testing models
(e.g. mice) are used to evaluate vaccine safety, potency and the durability of protection as well as to
uncover critical protective immune responses and to refine vaccination strategies.
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In the mid-nineties, genetic modification to create permanent
modifications in malaria parasite genomes was first described in
the rodent malaria parasite (RMP) Plasmodium berghei [1]. This
technology was extended to other Plasmodium species, includ-
ing the human malaria parasite P. falciparum, and was initially
used for loss-of-function analyses to uncover the function of
Plasmodium genes, including genes encoding potential vaccine
candidate antigens (reviewed in [2,3]). In addition to gene
disruption and gene mutation, methodologies have been
developed to create malaria parasites that express ‘foreign’
genes from other organisms, so-called transgenic parasites.
Among the first transgene mutants were RMP that expressed
fluorescent and luminescent reporter proteins. These parasites
have been used to visualize and analyze parasite growth and
development in vitro and in vivo and have been valuable tools
to analyze cellular and molecular features of malaria parasite
biology (reviewed in [4–7]). Transgenic rodent parasites have
also been used to provide mechanistic insights into host–para-
site interactions that regulate host (immune) responses to infec-
tion or those that mediate malarial pathology [8–13].
Transgenic parasites expressing fluorescent or luminescent
reporter proteins have been created in rodent malaria species,
the human parasite P. falciparum and the primate parasite P.
cynomolgi. These parasites have been exploited in screening
assays to measure (inhibition of) parasite growth at different
points of the parasite life cycle. Fluorescent and luminescent P.
falciparum parasites have been used in vitro to examine the
effect of drugs and other inhibitors on blood-stage growth
and on gametocytes [6,14–17]and fluorescent P. cynomolgi
parasites have been generated to screen for compounds that
target the hypnozoite stage in the liver [18]. Transgenic fluor-
escent and luminescent rodent parasites have been used in in
vitro screening assays to test inhibitors that target parasite
development in the blood and liver [6,19–22].
In addition to measuring growth inhibition in vitro, trans-
genic rodent parasites have been used to examine the impact
of drug or vaccine interventions in vivo, where inhibition of
parasite development is measured as the reduction of reporter
signal (mostly luminescent) in organs of the treated (compared
to unimmunized/untreated) rodent host [6,17,19,22,23]. As the
life cycle and basic biology of rodent and human Plasmodium
parasites are very similar and since the vast majority of genes
within their genomes are conserved [24], transgenic rodent
parasites are frequently used to evaluate protective immunity
against candidate Plasmodium antigens in vivo and are used to
assess different vaccine delivery platforms and vaccination regi-
ments. Several of these studies have been conducted in differ-
ent inbred mice strains that exhibit different, often polarized,
immunological responses to infection. Transgenic rodent para-
sites have been used in preclinical studies to examine protec-
tive immune responses to pre-erythrocytic (sporozoite and liver
stage) vaccines (see Section 2).
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More recently, transgenic rodent parasites have been gener-
ated that express proteins of the human Plasmodium species P.
falciparum and P. vivax. These so-called ‘chimeric’ parasites have
been used to evaluate the (in vivo) action of drugs against
human Plasmodium protein targets [25,26], to study malaria
pathology during pregnancy in vivo [27], and to evaluate the
protective efficacy of vaccines that target human Plasmodium
antigens (reviewed in [28–30] and see Table 1). In these vaccine
studies, mice are immunized with P. falciparum or P. vivax
antigens and subsequently challenged with chimeric rodent
parasites expressing the cognate P. falciparum or P. vivax anti-
gens. Such chimeric parasites permit an in vivo immunological
evaluation of novel target Plasmodium antigens and vaccination
strategies and can indicate the magnitude and type of protec-
tive immune response induced. This knowledge can be used to
down-select from candidate antigens under consideration
before proceeding to clinical studies [31].
Last, genetic modification of rodent and human malaria
parasites has also been used to generate parasites that arrest
in the liver. These parasites can provoke strong protective
immune responses in the host and are therefore being eval-
uated as live, attenuated vaccines [48–50].Many gene-deletion
rodent parasites have been tested in rodents for growth arrest
in the liver and for their capacity to induce potent protective
immune responses. These so-called genetically attenuated
parasites (GAPs) have been created in transgenic reporter
lines, which simplify the in vivo evaluation of both their safety
and protective efficacy. In order to generate completely safe
GAP vaccines, GAPs must be generated that completely arrests
in the liver. Consequently, multiple gene deletions in the same
GAP are considered necessary, each governing independent
but essential processes during liver-stage development.
Therefore, in order to generate and test a P. falciparum GAP
in human test subjects, large-scale screening of single and
multiple gene-deletion mutants in rodents is necessary to
identify suitable genes for deletion in P. falciparum.
In this review, we describe the use of transgenic malaria
parasites and their use as preclinical evaluation tools to measure
vaccine efficacy and immune responses after vaccination. We
describe: (i) transgenic rodent and human parasites that express
reporter proteins that have been used to evaluate immunogeni-
city of vaccine antigens and vaccine efficacy; (ii) the use of
transgenic chimeric rodent parasites, expressing antigens of P.
falciparum or P. vivax, to compare immunogenicity of vaccines
and vaccine strategies; and (iii) the use of transgenic parasites to
identify and evaluate GAP vaccines and to examine immunolo-
gical correlates of protection after vaccination in vivo.
2. Transgenic parasites expressing reporter proteins
Transgenic rodent and human malaria parasites that express
fluorescent and luminescent reporter proteins have been used
in screening assays to efficiently and rapidly measure inhibition
of parasite growth at different points of the parasite life cycle
[6,17,22,51]. These assays have been used to identify and char-
acterize anti-Plasmodium drugs and small-molecule inhibitors,
as well as vaccines targeting parasite development at different
points of the life cycle. Transgenic parasites expressing fluores-
cent or luminescent proteins have been generated in three
RMP, P. berghei, P. yoelii, and P. chabaudi. For P. berghei and P.
yoelii, a number of transgenic lines exist that express different
reporter proteins such as GFP, mCherry, or luciferase (or fusions
thereof). Most of these lines express these proteins under con-
trol of Plasmodium promoters of constitutively expressed
Plasmodium genes (often housekeeping genes), which creates
parasites that can be visualized and quantified throughout the
complete life cycle (Figure 1(a)). Frequently used promoter
regions of RMP genes include elongation factor 1-alpha
(eef1α), dihydrofolatereductase-thymidylate synthase (dhfr-ts), or
heat-shock protein 70 (hsp70). Information on all published RMP
transgenic lines can be found in the RMgm database of geneti-
cally modified rodent parasites (www.pberghei.eu).
Different assays have been developed to quantify parasite
growth using reporter parasites. To test the effect of inhibitors
on blood- and liver-stage growth, simple and rapid assays exist
that can quantify parasite numbers in blood samples, infected
hepatocytes, or in other tissues. For example, flow cytometric-
based assays counting GFP (or mCherry)-positive parasite-
infected red blood cells [20,52,53] (Figure 1(a)) or quantification
of luminescence signals to determine parasite numbers or para-
site loads in blood, liver, or other organs [19,21] (Figure 1(b)).
Infecting mice with defined numbers of luciferase expressing
parasites and subsequent quantifying parasite loads (lumines-
cence signal) in the liver by real-time imaging of live mice is
frequently used to establish the in vivo effect of either inhibitors
and vaccines on liver-stage development [6,17,22,23].
Bioluminescence imaging is simple to execute and can be
used to monitor the course of an infection without sacrificing
the animal [19] (Figure 1(b)). This reduces the number of ani-
mals required for experimentation because multiple measure-
ments can be made in the same animal over time that also
minimizes the effects of biological variation. In addition, since
imaged mice do not have to be sacrificed, additional features of
parasite development can be established, for example, charac-
teristics of the ensuing blood-stage infection such as the pre-
patent period, i.e. the duration between sporozoite infection
and a microscopically detectable blood infection.
As well as transgenic RMP lines, reporter parasites have
been generated for the human parasite P. falciparum.
Transgenic P. falciparum parasites expressing fluorescent or
luminescent proteins have been used to quantify blood-
stage growth in vitro in standard growth inhibition assays
(see below), to quantify parasite development in the mosquito
in standard membrane feeding assays to measure transmis-
sion-blocking (TB) activity and in high-throughput screening
of TB compounds against P. falciparum gametocytes (see
below). For the TB assays against mosquito stages and game-
tocytes, transgenic P. falciparum (NF54 strain) parasite lines
have been generated that express a GFP-luciferase fusion
protein under control of the strong constitutive hsp70 [54] or
the gametocyte-specific pfs16 promoter [55].
In addition to RMP expressing fluorescent and luminescent
proteins for vaccine studies, multiple transgenic RMP lines
expressing the model antigen ovalbumin (OVA) as an immu-
nological reporter have been created to study immune
responses after vaccination. Transgenic Plasmodium parasites
expressing OVA have been exploited to examine parasite-
specific CD8+T cell responses during both blood and liver







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT REVIEW OF VACCINES 687
infections [9,10,56–58]. For example, intravital two-photon
microscopy of livers of mice infected with P. berghei parasites
that express OVA and GFP in their cytoplasm showed that
transferred OVA-specific CD8 + T cells recognize and forms
clusters around infected hepatocytes, leading to the elimina-
tion of the intra-hepatic parasites [56]. In addition, analysis of
liver stage parasites expressing OVA, either in their cytoplasm
or exported to the parasitophorous vacuole membrane, in
conjunction with OVA-specific CD8+- and CD4+-OVA T cells
demonstrated that export of parasite proteins into the
infected hepatocytes enhanced immunogenicity and CD8+ T
cell based protection [10].
Below we describe the use of transgenic Plasmodium reporter
parasites in preclinical assays to evaluate different Plasmodium
vaccines and vaccination approaches that target the three major
points of the parasite life cycle: erythrocytic vaccines, transmis-
sion blocking vaccines, and pre-erythrocytic vaccines.
2.1. Erythrocytic vaccines
Although a number of RMP transgenic reporter parasites have
beenused in screening assays to evaluate drugs or other inhibitors,
notmany studies have reported the use of theseparasites in assays
to assess blood-stage vaccines. The inhibitory activity of sera from
(semi) immune individuals or purified immunoglobulins from vac-
cinated animals or people is mostly evaluated in P. falciparum
using in vitro erythrocyte reinvasion and growth inhibition activity
assays (GIA assays). These assays are used to quantitatively mea-
sure antibody-mediated effects on parasite invasion and growth,
often in small-scale synchronized cultures of blood-stage parasites
that are maintained in microtiter plates for 1–2 cycles in the pre-
sence or absence of antibodies. Determination of inhibition of
invasion and growth in these assays is mainly performed by (auto-
matic and high-throughput) microscopic, enzymatic, or flow cyto-
metric assays using wild-type P. falciparum parasites [30,59–61]. In
one study, a flow cytometric assay was developed that used
transgenic P. falciparum parasites expressing GFP [16]. In this
study, P. falciparum parasites of the D10 strain were genetically
modified to express GFP under control of the constitutive Pfhsp86
promoter and inhibition of parasite growth by inhibitory antibo-
dies and human serumwas determined bymeasuring parasitemia
by flow cytometry. This assay was superior to microscopy-based
approaches and comparable to DNA-staining-based techniques to
quantify growth inhibition (Figure 1(c)).
2.2. Transmission blocking vaccines
Mutant RMP are frequently used in (loss-of-function) studies
that aim to identify and characterize Plasmodium proteins
essential for parasite development in mosquitoes, which may
be suitable targets for TB vaccine strategies. Often these dele-
tion mutants have been created in transgenic RMP that
express fluorescent or luminescent reporters, under control
of constitutive stage-specific promoters permitting a detailed
examination of parasite development in the mosquito, for
example, enabling easier quantification of gametocyte devel-
opment, fertilization, and oocyst or sporozoite production.
While the use of transgenic RMP in TB vaccine studies is






































































































































































































































































































































































































































































































































































































































































































































































































688 A. S. OTHMAN ET AL.
protein P25 of P. vivax and P. falciparum have been used in
direct mosquito feeding (DMF) assays for evaluation of the
efficacy of vaccines targeting P25 of P. vivax and P. falciparum.
In these assays, immunized mice were challenged with the
chimeric RMP parasites expressing the human antigen, fol-
lowed by determination of oocyst reduction in mosquitoes
Figure 1. The use of transgenic reporter parasites in malaria vaccine research.
(a) Representative fluorescent images of different life cycle stages of P. falciparum and P. berghei (mCherry and GFP) reporter parasites. Blood stage trophozoites (Tr);
schizonts (Sc); dissected infected mosquito midguts (Mid) with mature oocysts (Oo); salivary gland sporozoites (Spz); P. berghei liver stage schizont (LS). Host and parasite
DNA are stained with Hoechst or DAPI (blue).(b) Representative rainbow images of luminescence intensity in blood (upper panels) or liver (bottom panels) of live mice
either uninfected (U) or infected (I) with luminescent reporter parasites. Parasite density (luminescence intensity) can also be determined in extracted tissue (ex vivo); lungs
(lg), kidney (K), adipose/fat tissue (F), liver (Lv), spleen (S), brain (B) and heart (H). Bottom panel shows luminescence in extracted livers of infected and uninfected mice, 48 h
after infection with sporozoites.(c) Schematic representations showing the use of transgenic reporter parasites in assays to determine efficacy of erythrocytic, transmission
blocking (TB) and pre-erythrocytic (sporozoite and liver stage) vaccines. Erythrocytic Vaccines: The inhibitory activity of sera from (semi) immune individuals or purified
immunoglobulins from vaccinated animals/people on parasite invasion and growth in red blood cells are frequently determined in Growth Inhibition Assays (GIA). GFP
expressing P. falciparum parasites have been used in GIA where inhibition of parasite growth was determined by measuring parasitemia by flow cytometry. Transmission
Blocking Vaccines: The standard membrane-feeding assay (SMFA) is a well-established method to evaluate the activity of antibodies/serum against human malaria
parasites in the mosquito, mainly quantified by determination of oocyst production. A transgenic reporter P. falciparum line expressing luciferase has been used in SMFA to
quantify oocyst production in mosquitoes, thus eliminating the need for mosquito dissections. Pre-erythrocytic (sporozoite and liver stage) vaccines: Assays employing
luciferase-expressing RMP have been developed to visualize and quantify liver stage development. Quantification of parasite liver loads by real time imaging has been
performed in vaccinated and unvaccinated mice that have been challenged with luminescent parasites that either only express luciferase (e.g. in GAP studies; Section 4) or
also express human malaria proteins (e.g. in studies on human malaria vaccines; Section 3). Full color available online.
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that were fed on the immunized and challenged mice
[37,38,46,59,62].
The standard membrane-feeding assay (SMFA) is a well-
established and recognized method to evaluate TB activity of
antibodies/serum against human malaria parasites [63]. This
assay has been utilized widely to assess the TB activity of
purified antibodies and serum, both in preclinical and clinical
vaccine studies. TB activity in the SMFA is defined by the
reduction in oocyst numbers in mosquitoes that have been
fed with infected blood containing gametocytes in the pre-
sence of antibodies/serum compared to no (or control) anti-
bodies (Figure 1(b)). Often oocyst production is measured by a
microscopic analysis of dissected mosquito midguts. Recently,
a transgenic reporter P. falciparum line expressing luciferase
has been used in SMFA to quantify oocyst production in
mosquitoes, thus eliminating the need for mosquito dissec-
tions [54]. This transgenic line was made in parasites of the P.
falciparum NF54 strain and expresses a fusion protein of GFP
and luciferase which is under control of the constitutive
Pfhsp70 promoter and parasites of this line do not express a
drug-selectable marker. This novel dissection-free lumines-
cence-based SMFA method, using a transgenic P. falciparum
reporter parasite which is not resistance to known antimalar-
ials, makes this assay much more amenable to high-through-
put screening for both TB drugs and vaccines.
2.3. Pre-erythrocytic vaccines
Transgenic RMP are frequently used in preclinical sporozoite and
liver-stage vaccine studies. Simple and sensitive in vitro and in
vivo assays employing luciferase-expressing P. berghei and P.
yoelii parasites have been developed to visualize and quantify
liver-stage development [19,22]. In these assays, parasite hepatic
development is determined by bioluminescence measurement
of cultured liver stages or by real-time imaging of luminescence
emanating from the liver of live mice. These measurements
correlate well with established (but more laborious) quantitative
RT-PCR methods [64,65]. Both in vitro and in vivo luminescence
imaging assays have been used to screen inhibitors and vaccines
against liver stages (Figure 1(c); [23,29,31,66,67]). The simplicity
and speed of quantitative analysis of parasite liver loads by real-
time imaging and the possibility to analyze parasite develop-
ment in live mice without surgery greatly enhances the analysis
of the effect of individual vaccines or vaccine strategies that
target pre-erythrocytic stages. Quantification of parasite liver
loads by real-time imaging has been performed in mice that
have been first vaccinated with human Plasmodium subunit
vaccines and then challenged with luminescent chimeric RMP
that express human parasite antigens (see Section 3) or in mice
that have been immunized with GAPs and subsequently chal-
lenged with luminescent RMP (see Section 4). In addition, ima-
ging of luminescent parasites in mice has been successfully used
to examining host factors regulating liver infections [68] and to
analyze the impact of immune responses on inhibition of liver-
stage development [23,69–71]. Such studies have revealed the
importance of adaptive and innate immune responses in protec-
tive immunity after vaccination. In these studies, passively or
actively immunized mice (including immunological compro-
mised mice) were challenged with luciferase-expressing
parasites to monitor reduction in parasite liver loads. In addition
to the use of luminescent RMP, transgenic RMP expressing fluor-
escent proteins have been used to provide insight into interac-
tions of sporozoites with cells in lymph nodes and with dermal
tissue and blood vessels, and their interactions specifically with
cells of the innate and adaptive immune system [72–77]. Using
fluorescent P. berghei sporozoites, it was demonstrated that
fewer sporozoites enter the blood and reach the liver in sporo-
zoite-immunizedmice than naïve mice. Specifically, high circum-
sporozoite protein (CSP) antibody titers were shown to affect
sporozoite motility in the skin, preventing immobilized sporo-
zoites of entering dermal blood vessels [78].
No assays have yet been reported to analyze P. falciparum liver-
stage development in vitro with fluorescent or luminescent para-
sites. Most studies on P. falciparum liver stages, either cultured in
hepatocytes (primary human or HC-O4 hepatocytes) or in chimeric
mice with human liver tissue, have used wild-type parasites that
were analyzed by RT-PCR or by microscopy of fixed and stained
cells. One study reported the use of transgenic P. falciparum para-
sites that express luciferase to study liver infection in immune
compromised mice engrafted with human liver tissue [70]. This
FRG huHep mouse is susceptible to a P. falciparum sporozoite
infection and supports complete liver-stage development. The
reporter P. falciparum (NF54) parasites express a gfp-luciferase
fusion gene under theconstitutivePfeef1a promoter and the repor-
ter expression cassette is introduced into the pf47 locus [79]. In this
study [70], a clear effect could be detected on infection of livers of
FRG huHep mice by passively transferred antibodies against CSP
and parasite liver loads in these mice were analyzed using biolu-
minescence imaging 6 days after infection with sporozoites (i.e. at
the peak of liver-stage luciferase activity).
3. Chimeric rodent parasites expressing human
plasmodium proteins
In addition to transgenic reporter parasites, rodent parasites
expressing human malaria parasite proteins (HMP; P. falci-
parum and P. vivax) have been used in vaccine studies.
These ‘chimeric’ RMP are used both to analyze immune
responses against HMP antigens and to evaluate in vivo pro-
tective efficacy of vaccines that target HMP antigens (reviewed
in [28,29] and see (Table 1). The preclinical evaluation of
protective immunity involves mice being immunized with
vaccines targeting different P. falciparum or P. vivax antigens
followed by challenge with chimeric rodent parasites that
express the corresponding HMP antigen. Mainly chimeric
RMP expressing pre-erythrocytic HMP antigens have been
generated (Table 1). Chimeric parasites have also been used
to study immunogenicity and protective efficacy of transmis-
sion blocking HMP vaccine antigens, i.e. P. falciparum and P.
vivax P25 [37,38,46] and blood-stage vaccine antigens, i.e. P.
falciparum MSP1 (Table 1).
Generation of chimeric parasites have been performed
using standard methods of RMP transfection [80] by introdu-
cing HMP genes into the RMP genome, either as additional
gene copies or by replacing the complete RMP with its HMP
ortholog [29]. In addition, chimeric parasites have been gen-
erated that express fusions of the RMP and HMP orthologous
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genes (Table 1). The recently described gene insertion-marker
out (GIMO) transfection method [81] greatly simplifies and
speeds up the generation of transgenic parasites expressing
heterologous proteins, which are free of drug-selection marker
genes. Using this method, two principle types of chimeric RMP
expressing HMP proteins have been created ([29]; Figure 2(a)).
The first type are ‘additional copy mutants;’ here, the HMP
gene is introduced as an additional gene copy into a silent/
neutral locus of the GIMO mother-line and the HMP gene is
under the control of a constitutive or stage-specific RMP gene
promoter. This strategy is often used when an ortholog of the
HMP gene is absent from the RMP genome. The second type
of chimeric parasites are ‘replacement mutants;’ here, the
coding sequence (CDS) of the RMP gene is replaced with the
CDS of the orthologous HMP gene. This method creates chi-
meric parasites expressing the HMP gene under control of the
endogenous RMP gene promoter and transcriptional termina-
tor. The absence of a drug-selectable marker in both the
additional copy and replacement mutants makes it possible
to rapidly introduce additional genetic modifications in these
chimeric parasites, e.g. introduction of additional HMP genes
or fluorescent/luminescent reporter genes.
Chimeric parasites have been used in vaccine studies for a
number of reasons. While a high level of genetic orthology exists
between genes of RMP and HMP, critical differences often exist in
the sequence and structure of the encoded proteins [24]. In addi-
tion, HMPexpress a number of genes encoding vaccine candidates
that are absent fromRMP [24,31]. These differences complicate the
analysis of immunogenicity and protective efficacy of HMP anti-
gens in rodentmodels and compromise the effective translation of
findings into a human malaria vaccine. Therefore, ‘humanizing’
RMP by introducing HMP genes into rodent parasite genomes
can help to circumvent some of these problems. HMP cannot
readily infect small animals and testing of P. falciparum parasites
in rodents is expensive as it is largely restricted to immune-defi-
cient mice (i.e. DRAG or FRG) transplanted with human hemato-
poietic stem cells and/or liver tissue [82,83]. While it is possible to
test both pre-erythrocytic and blood-stage P. falciparum vaccine
candidates directly in human subjects, these studies are expensive
and laborious to perform and therefore less suitable for larger
screening studies [84]. Preclinical screening studies using chimeric
RMPmake it possible to rapidly evaluate and compare the protec-
tive efficacy of novel target antigens and vaccination strategies in
order to down-select candidate antigens and strategies that can
proceed into clinical studies.
Recently, 10 pre-erythrocytic P. falciparum vaccine candi-
date antigens were tested for their protective efficacy using
chimeric parasites [31]. The antigens were selected based on
published literature, immuno-profiling, and expression studies.
Mice, immunized with viral-vectored vaccines expressing the
HMP antigens, were challenged with chimeric parasites for
evaluation of protective immune responses and characteriza-
tion of the immune responses (see Figure 2(b) for the immu-
nization/challenge protocol). In this study, two antigens,
PfLSA1 and PfLSAP2, generated better protective efficacy
than two leading pre-erythrocytic P. falciparum vaccine anti-
gens, PfCSP or PfTRAP, in both inbred BALB/c and outbred CD-
1 mice. The chimeric parasites used in this study had the HMP
gene introduced as an additional gene copy as a number of
the selected genes did not have an ortholog in the P. berghei
genome, thereby excluding the possibility to make replace-
ment mutants. A number of other chimeric RMP have been
used, which express a HMP ortholog in place of their own RMP
gene (Table 1), for example chimeric parasites expressing pre-
erythrocytic vaccine candidates such as P. vivax and P. falci-
parum CSP and CelTOS ([34,39,41,85]; Table 1).
Chimeric parasites have also been used to evaluate immu-
nogenicity of antigens against other lifecycle stages (i.e. TB
vaccines see Figure 2(c)) as well as being used to evaluate
different vaccine delivery platforms and to optimize the vacci-
nation strategy and schedule. For example, the use of a single
chimeric parasite expressing two HMP genes, TRAP and UIS3,
showed that combination of two vaccines expressing these
antigens could protect 100% of immunized mice, despite
these antigens demonstrating only modest protective immunity
when administered as a single antigen formulation [32]. This
synergistic effect was only evident when the two vaccines were
mixed and administered into two legs. Another study, testing
different vaccine delivery platforms targeting P. vivax CSP using
chimeric RMP that expressed P. vivax CSP, demonstrated that
superior immunogenicity was generated by virus-like particles
(VLP) expressing P. vivax CSP compared to other formulations,
including viral-vectored vaccines or protein plus adjuvant [40].
Chimeric parasites expressing either full-length HMP proteins
or fusions of HMP-RMP proteins can be instructive in determin-
ing critical immunological determinants of the protective
immune responses after vaccination, for example, in GIA using
material obtained from immunized humans or animals
[43,86,87]. However, the mechanisms of protection after vaccina-
tion can be lost in in vitro assays if only individual components of
the adaptive immune response are examined in isolation. For
example, responses that require both antibody and cell-
mediated responses, either acting independently or when they
work in concert such as in antibody-dependent cell-mediated
cytotoxicity responses [88]. Ultimately, however, even positive
results generated using chimeric parasites in rodents or in vitro
assays will need to be validated in human vaccine trials.
4. Attenuated parasite vaccines
Transgenic parasites have not only been used for development
and evaluation of immunogenicity of antigens and protective
immunity of subunit vaccines, they have also been used to
develop and evaluate whole-organism vaccines consisting of
(genetically) attenuated parasites. Vaccination with live, attenu-
ated, sporozoites has been shown to induce strong protective
immune responses both in rodents and in humans (reviewed in
[48]). Sporozoite attenuation has been performed by radiation or
by genetic modification of parasites (reviewed in [48–50,89,90]).
A prerequisite for induction of protective immunity is that the
attenuated sporozoites enter the liver, since heat-killed or over-
irradiated sporozoites that do not invade hepatocytes do not
efficiently confer protection [49,91]. These so-called GAPs have
genes encoding proteins essential for parasite development in
the liver removed, thereby producing parasites that arrest in the
liver. For both GAPs and radiation-attenuated parasites, immu-
nogenicity (protective efficacy) and safety are critical factors for
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further clinical development as whole-organism vaccines.
Transgenic rodent parasites have been used extensively in pre-
clinical evaluation studies to establish the safety profile of GAPs,
i.e. absence of a blood-stage infection in mice after inoculation
with high numbers of GAPs [50]. A number of different GAP
vaccine candidates have been generated in rodent parasites, by
deletion of either single or multiple genes. These have been
analyzed in mice to ensure they completely arrest in the liver
and therefore meet the necessary safety profile for translation
into human GAP. Introducing genes encoding fluorescent and
luminescent genes into the genomes of GAPs has permitted a
detailed analysis on the timing and magnitude of arrest in the
liver [92,93] (Figure 1(b)). Based on studies on growth arrest and
safety of rodent GAPs, three multiple gene-deletion P. falciparum
GAPs have been developed that have advanced into clinical
evaluation [94–96].
In addition to examining the safety profile of a GAP, trans-
genic RMP have also been used to evaluate the protective
immunity induced by attenuated sporozoites, both radiation-
attenuated sporozoites and GAPs. In multiple studies, mice
immunized with attenuated parasites have been challenged
with fully infectious sporozoites that express luciferase to
determine liver loads by real-time imaging, similar to what
has been described above for evaluation of protective immu-
nity of subunit vaccines (Sections 2 and 3; Figure 2(b)).
Quantification of parasite liver loads and the pre-patent period
provide a direct measurement of protective immunity induced
by different immunization regimens.
Figure 2. The use of chimeric RMP expressing human malaria parasite (HMP) proteins in malaria vaccine research.
(a) Additional Copy Mutants have the HMP gene (e.g. the P. falciparum gene coding sequence; Pf CDS) introduced as an additional gene copy into a silent/neutral
locus of the RMP; the HMP gene is under the control of a constitutive or stage-specific RMP gene promoter. Replacement Mutants have the RMP coding sequence
(Pb CDS) replaced by the orthologous HMP CDS. This often 2 step replacement method, employing the methods of GIMO transfection, creates chimeric parasites
expressing the HMP gene under control of the endogenous RMP gene promoter and transcriptional terminator.(b) Vaccine immunogenicity and protective efficacy
measured in mice immunized with HMP liver stage sub-unit vaccines or rodent GAPs. Immunized (and naïve) mice are challenged either with luminescent chimeric
RMP expressing the cognate HMP antigen or with luminescent ‘wild-type’ RMP. Protective efficacy, relative to unvaccinated mice, is quantified by measuring the
parasite load by real time imaging of the liver of live mice at 44–48 h after challenge with sporozoites (in vivo imaging of luminescence) and/or measuring the time
to establish a detectable blood stage infection (pre-patent period; % survival).(c) Vaccine efficacy of HMP transmission blocking vaccines determined in a direct
mosquito feeding assay (DMFA) in mosquitoes. In these assays mice are immunized with the HMP transmission blocking vaccine. Immunized and naïve mice are
then infected with chimeric RMP parasites expressing the cognate HMP antigen. The infected mice are used to feed mosquitoes and (reduction in) oocyst production
in mosquitoes is quantified 8–10 days after feeding in order to measure of the transmission blocking potential of the HMP vaccine.
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Rodent GAPs expressing luciferase have also been used to
investigate different attenuated sporozoite administration
strategies [97,98]. These studies demonstrated that the route
and dose of administration of attenuated sporozoites are cri-
tical factors in inducing protective immunity. Intradermal, sub-
cutaneous, and intramuscular administration of attenuated
sporozoites resulted in reduced parasite liver loads when
compared to the same number of sporozoites introduced
intravenously. Lower parasite liver loads after intradermal
delivery was associated with reduced protective efficacy com-
pared to intravenous immunization. Transgenic fluorescent
rodent GAPs have been used to analyze direct interactions of
lymphocytes with infected hepatocytes using intravital ima-
ging of mice that had previously been immunized with atte-
nuated sporozoites [13,56,99,100]. These studies have revealed
the importance of CD8+ T-mediated killing and elimination of
infected hepatocytes in mice immunized with attenuated
sporozoites. Further, using transgenic RMP expressing the
immunological reporter protein ovalbumin, it has been possi-
ble to analyze direct interactions and effects of antigen spe-
cific CD8+ T cell-mediated immune responses in the liver of
mice immunized with attenuated sporozoites ([10,56]; see also
Section 2).
5. Expert commentary
The ability to genetically manipulate the malaria parasite by
deleting, mutating genes, or introducing transgenes in the
parasite genome has advanced our understanding of the
molecular and cellular biology of malaria parasites for the
last 20 years. Genetic modification has been central to the
functional characterization of genes including genes encoding
putative vaccine candidate antigens. The generation of repor-
ter parasites with additional genes in their genome has
resulted in the increased use of transgenic parasites in transla-
tion-oriented research, for example, in preclinical studies eval-
uating immunogenicity and protective efficacy of novel
antigens and vaccines. These studies involve transgenic para-
sites of both rodent and human malaria species. Two exam-
ples of transgenic human parasites are luminescent P.
falciparum parasites that have been used in high-throughput
assays to quantify transmission blocking activity and the use
of luminescent P. falciparum parasites to analyze the effects of
(passively transferred) immune sera on liver infection in mice
engrafted with human liver tissue (Section 2). These assays are
used to generate insights into the immunogenicity of putative
vaccine candidate antigens, knowledge which in turn can be
used to improve vaccine strategies that target transmission
blocking stages and pre-erythrocytic stages, respectively.
Compared to transgenic P. falciparum parasites, transgenic
RMP have been more widely applied in experimental vaccine
studies, especially in the evaluation of pre-erythrocytic anti-
gens and to assess different pre-erythrocytic vaccination stra-
tegies. For example, luminescent parasites are frequently used
to challenge immunized mice in standard assays that measure
the reduction in parasite liver load as a consequence of the
protective immune responses induced by different antigens or
vaccine strategies. Another example is the application of intra-
vital imaging using fluorescent parasites in immunized mice,
which has revealed critical insights into the immune response
targeting sporozoites and infected liver cells (Section 2). Such
in vivo assays to analyze crucial protective immune responses
after vaccination and to evaluate protective immunity are
valuable tools to improve pre-erythrocytic vaccines.
In addition to reporter rodent parasites, chimeric rodent
parasites expressing proteins of the human malaria parasites P.
falciparum and P. vivax are now being increasingly used in
vaccine studies. Chimeric RMP expressing HMP proteins are
used to determine protective efficacy in mice immunized with
different subunit vaccines expressing P. falciparum and P. vivax
antigens (Section 3). These studies have been used to select
novel vaccine candidate antigens for advancement into clin-
ical trials. Chimeric RMP can not only support identification of
novel antigens, but also contribute to the in vivo evaluation of
novel delivery platforms and vaccine strategies, both for vac-
cines targeting pre-erythrocytic parasites and transmission
blocking vaccines (Section 3). The use of chimeric rodent
parasites to evaluate protective immunity or transmission
blocking immunity is not without its limitations. First, the use
of chimeric RMP still relies on a murine model, often inbred
mice strains, and encounter issues related to restriction of
MHC epitopes and marked immune dominance of certain
epitopes [101]. Outbred mice can possibly be used to more
accurately reflect what may be seen in humans but it is
possible that some antigens identified as poorly immunogenic
in these studies may in fact be immunogenic in humans.
Second, when using ‘additional copy’ chimeric parasites, the
HMP gene expression is dependent on the RMP promoter
used, which is unlikely to exactly mimic the timing and mag-
nitude of the expression of the HMP protein in the HMP. In
studies where multiple vaccine antigens are examined, the
chimeric parasites will express the different HMP antigens at
the same level, which is unlikely to be the case in wild-type
HMP. Therefore, where possible, it would be useful to also
compare protective vaccine efficacy in mice using a chimeric
RMP parasite where the HMP antigen expression matches its
expression in the HMP, both in timing and magnitude. Despite
these limitations, chimeric RMP allow for rapid vaccine (rank-
order) screening in vivo and can provide critical insights into
both the importance of the vaccine target and the mechanism
of protection. Indeed data from chimeric RMP are being used
to justify the selection of novel HMP antigen vaccines (and
delivery platforms) to advance into clinical testing.
In addition to the role of transgenic parasites in the devel-
opment of subunit vaccines, transgenic parasites have played
a central role in the development and evaluation of whole-
organism vaccines consisting of attenuated sporozoites.
Studies in rodent malaria models on the safety and immuno-
genicity of GAPs have formed the basis of the development of
different (multiple gene deletion) P. falciparum GAPs that have
now advanced into clinical trials (see Section 4). Given the
data from rodents studies with both GAPs and irradiated
sporozoites and from data emerging from irradiated sporo-
zoite vaccine research in humans, it is anticipated that further
improvements can be made to increase GAP potency. Here
again, transgenic RMP can play an important role, for example,
to optimize the routes of attenuated parasite vaccine admin-
istration (e.g. studies with devices to improve intradermal or
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intramuscular delivery, use of adjuvants, etc.) and in develop-
ment of the so-called ‘next-generation’ GAP vaccines with
increased potency requiring fewer sporozoites per dose and
fewer vaccination doses to achieve sustained sterile protection
(e.g. GAPs which arrest late into liver-stage development).
Transgenic parasites used in conjunction with ‘humanized’
animal models or in sophisticated in vitro assays are designed
to aid and speed up malaria vaccine design, specifically to
suggest potential priorities for expensive and time-consuming
clinical trials. As mentioned above, however, the predictive
power of these assays can only be determined after human
trials have been performed and lessons learnt from the success
and discrepancies that will arise. In addition, over-reliance on a
single experimental model may result in putative valid vaccine
targets not being advanced further, as they did not generate
sufficient immunity in the testing platform (e.g. in mice).
6. Five-year view
Despite considerable effort, over decades, a highly effective
vaccine against malaria still does not exist. This is in part due
to the limited number of antigens and methods of immuniza-
tion that have advanced into clinical testing. Most vaccine
studies have focused on a limited number of antigens but for
a broad acting, highly durable, and potent malaria vaccine, this
is likely to be too restrictive and insufficient to provide the
protection required. Therefore, in order to create multi-antigen
and multi-stage vaccines, many more antigens and improved
vaccine delivery platforms will need to be investigated and
evaluated as a priority in the next 5 years. In addition, the
critical host and parasite factors mediating protective immunity
and those that are necessary for maintaining durable protection
need also further investigation in the upcoming years. The use
of transgenic parasites in conjunction with other enabling tech-
nologies (e.g. genetic modification of mice or human cell lines,
advances in imaging, etc.) has opened up new possibilities and
will be used to contribute to a more rapid preclinical evaluation
of vaccines, vaccination strategies, and identification of critical
factors of protective immune responses. Transgenic P. falci-
parum parasites expressing luminescent reporter proteins are
currently valuable tools to assess drugs and inhibitors against
the parasite in high-throughput assays and are now also being
used to test the immunogenicity of (novel) transmission block-
ing antigens and will continue to be used to evaluate novel
transmission blocking vaccine strategies. In addition, the recent
availability of luminescent P. falciparum parasites that express
luciferase under strong promoters (i.e. constitutive, sporozoite
or liver-stage specific) will act as a bridge between rodent and
clinical studies. They will be increasingly used in assays to
evaluate the effects of (human) immune serum, cells, and fac-
tors on P. falciparum blood and liver cell infection, both in
cultured cells and in humanized mice with human hematopoie-
tic and human liver cells. Such assays will contribute to gener-
ate essential insights into the immunogenicity of (in particular
pre-erythrocytic) antigens and vaccination strategies. Both
reporter RMP expressing fluorescent and luminescent proteins
as well as chimeric RMP expressing HMP antigens will contri-
bute to these studies examining protective immune responses
in particular of vaccine strategies targeting pre-erythrocytic
vaccines. The use of transgenic parasites may not only help to
rank order existing candidates but also help to reveal novel
vaccine candidate antigens and vaccination strategies. Loss of
function and protein-tagging mutants often reveal parasite
proteins that have critical roles in parasite development or, for
example, are located on the surface of extracellular forms of the
parasite and may therefore be vulnerable to antibody-based
vaccines. Uncovering critical protective immune responses and
efforts to establish correlates of protection after vaccination
may be greatly aided by the use of both transgenic parasites
and humanized mice, which could be used to examine both the
induction and recall of immune responses in different organs.
Transgenic RMP will continue to play an important role in
preclinical evaluation of novel attenuated sporozoite vaccines
both in studies to develop GAPs that are more immunogenic
and in studies to improve vaccination strategies (e.g. optimizing
the route of administration). In particular, next-generation P.
falciparum GAPs that have been further modified to express
multistage and antigens from multiple strains.
Key issues
● Most vaccine studies have focused on a limited number of
antigens but for a broad acting, highly durable and potent
malaria vaccine this is likely to be too restrictive and insuffi-
cient to provide the protection required. Multi-stage, multi-
ple-antigen sub-unit or genetically attenuated parasite
vaccines may provide a solution.
● Transgenic (human and rodent) malaria parasites expres-
sing ‘foreign’ proteins, for example fluorescent and lumi-
nescent proteins, have been used to determine the
protective efficacy of different antigens and to evaluate
vaccination platforms/strategies.
● Transgenic parasites (e.g. expressing OVA) are being used
to understand the critical determinants of protection after
vaccination; specifically to examine the induction and recall
of protective immune responses in the blood and the liver
● Luminescent rodent parasites are now increasingly used to
challenge vaccinated mice, and non-invasive measurements
of parasite liver load permits examination of both the pro-
tective responses generated by different antigens and to
evaluate novel vaccine strategies.
● Luminescent P. falciparum parasites are being used both in
high-throughput assays to quantify transmission blocking
activity and to analyze the effects of human immune sera/
immunoglobulins on parasite development in the liver of
humanized mice.
● Chimeric rodent parasites, expressing P. falciparum or P.
vivax antigens, are being used to directly evaluate and
rank-order human malaria vaccine candidates and determi-
nation of the most suitable for clinical testing.
● Chimeric rodent parasites permit an in vivo comparison of
different P. falciparum/vivax vaccine delivery platforms and
vaccination strategies; they are being used to determine the
best combination of antigens, delivery system and immuni-
zation protocol to move forward into clinical testing.
● Transgenic parasites play a central role in the development
and evaluation of whole organism vaccines consisting of
694 A. S. OTHMAN ET AL.
attenuated sporozoites. Both in evaluation of safety and in
assessing protective efficacy. Improvements in genetically
attenuated parasite vaccines and strategies for vaccination
(i.e. optimizing the route of administration) will continue to
require the use of transgenic parasites
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